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Abstract
 
The activating Ly-49D receptor and the inhibitory Ly-49A receptor mediate opposing effects
on natural killer (NK) cell cytotoxicity after interaction with the same major histocompatibility
 
complex ligand, H2-D
 
d
 
. To compare Ly-49D and Ly-49A interactions with H2-D
 
d
 
, we cre-
ated mutations in H2-D
 
d
 
 and examined the functional ability of these mutants to activate lysis
through Ly-49D or to inhibit lysis through Ly-49A. Specific single amino acid changes in ei-
 
ther the H2-D
 
d
 
 
 
a
 
1
 
 helix or the 
 
a
 
2
 
 helix abrogated Ly-49D–mediated cytotoxicity, but these
changes had no significant effect on Ly-49A–dependent inhibition. Each of three 
 
a
 
2
 
 domain
mutations in the floor of the peptide binding groove reduced functional recognition by either
Ly-49D or Ly-49A, but all three were required to fully abrogate inhibition by Ly-49A. Our
studies indicate that Ly-49D/H2-D
 
d
 
 interactions require distinct determinants compared with
Ly-49A/H2-D
 
d
 
 interactions. These differences have important implications for the integration
of activating and inhibitory signals in NK cells.
Key words: natural killer cells • major histocompatibility complex • receptors • cytotoxicity • 
rodent
 
Introduction
 
NK cell function is regulated by a balance of signals deliv-
ered through activating and inhibitory receptors (1). NK
cytotoxicity is generally inhibited by class I MHC (MHC I)
on targets, but recent studies have identified both inhibi-
tory and activating receptors for MHC I encoded within
the same gene families (1).
In mice, the Ly-49 gene family includes both inhibitory
and activating receptors for MHC I, expressed on overlap-
ping subsets of NK cells (2, 3). Two members of this recep-
tor family, Ly-49A and Ly-49D, recognize the same MHC
I allele, H2-D
 
d
 
, but mediate opposing effects; Ly-49A in-
hibits NK function, whereas Ly-49D activates it (4–6). Ly-
49A and Ly-49D are 86% homologous in the extracellular
domain, and mAb specific for the 
 
a
 
1
 
/
 
a
 
2
 
-H2-D
 
d
 
 domains
blocks functional interaction of H2-D
 
d
 
 with either Ly-49A
or Ly-49D (4–7).
To compare structural requirements for functional rec-
ognition of H2-D
 
d
 
 by Ly-49D and Ly-49A, we prepared a
 
series of mutated H2-D
 
d
 
 molecules in which specific
H2-D
 
d
 
 residues were altered to the corresponding residue
in H2-D
 
b
 
 (not a ligand for either Ly-49A or Ly-49D; refer-
ences 4, 6). We expressed these mutants in the rat target
YB2/0 and examined their functional interaction with
mouse Ly-49A or Ly-49D expressed on rat RNK-16 cells.
We found that single amino acid mutations throughout the
 
a
 
1
 
 and 
 
a
 
2
 
 helices interrupted recognition of H2-D
 
d
 
 by Ly-
49D but not Ly-49A. Combinatorial mutagenesis of 
 
a
 
2 
 
res-
idues in the 
 
b
 
-pleats was required to abrogate functional
recognition of H2-D
 
d
 
 by Ly-49A. Thus, this opposing re-
ceptor pair demonstrates distinctions in their requirements
for ligand recognition.
 
Materials and Methods
 
Cells.
 
RNK-16, YAC-1, and YB2/0 were cultured in
cRPMI-1640. RNK-16 transfectants RNK.Ly-49A and
RNK.Ly-49D have been described previously (6, 8).
 
Antibodies and Flow Cytometry.
 
mAbs A1 (anti–mouse Ly-
49A), PK136 (anti-NK1.1), 12A8 (anti–mouse Ly-49D and anti–
mouse Ly-49A–specific), 2C7 (antiovalbumin), and 34-5-8S
 
(anti–H2-D
 
d
 
-
 
a
 
1
 
/
 
a
 
2
 
) were partially purified from ascites by am-
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d
 
monium sulfate precipitation. Anti–H2-D
 
d
 
-
 
a
 
3
 
 (34-2-12S) was
from PharMingen. F(ab
 
9
 
)
 
2
 
 fragments were generated by pepsin
digestion as previously described (6). Flow cytometry analysis
used a Becton Dickinson FACScan™.
 
Cytotoxicity Assays.
 
NK cytolysis of targets was assessed in
triplicate using standard 4-h 
 
51
 
Cr-release assays (8). For mAb inhi-
bition, effectors were preincubated 15 min at room temperature
with F(ab
 
9
 
)
 
2
 
 (25 
 
m
 
g/10
 
6 
 
effectors) or intact antibody (10 
 
m
 
g/10
 
6
 
effectors) before target addition. Results shown are representative
of at least three separate experiments.
 
H2-D
 
d
 
 Mutations.
 
Mutations S73W, T80N, A81L, R83G,
and N86Q were generated using standard recombinant PCR
with overlapping primers encoding the mutation, with external
5
 
9
 
 primer-CTGCTCCTGCTGCTGGCGGCCGCCCTG and
external 3
 
9
 
 primer-AGCCCAGGGCCCAGCACC, using 
 
Pwo
 
polymerase (Roche) and H2-D
 
d
 
 cDNA as template (pD
 
d
 
SEL.FIX
34; a gift from F. Karlhofer, University of Vienna, Vienna, Aus-
tria). The 646-bp PCR fragment replaced the corresponding
fragment in wild-type H2-D
 
d
 
 cDNA in pD
 
d
 
SEL.FIX 34 by re-
striction sites 5
 
9
 
-NotI/3
 
9
 
-ApaI. The mutated H2-D
 
d
 
 cDNA was
excised 5
 
9
 
-SalI/3
 
9
 
-EcoRI, and ligated into the expression vector
pH
 
b
 
APr-1-neo, 5
 
9
 
-SalI/3
 
9
 
-HindIII, after 3
 
9
 
 Klenow treatment.
Other mutations were created using the QuikChange Site-Directed
Mutagenesis kit (Stratagene) using overlapping primers encoding
the mutation in H2-D
 
d
 
-PUC19. Mutated H2-D
 
d
 
 cDNAs were
subcloned into the expression vector BSR
 
a
 
EN (a gift from A.
Shaw, Washington University, St. Louis, MO). All mutations
were verified by sequencing.
 
Transfections.
 
YB2/0 were transfected as previously described
(8, 9) and selected for similar expression levels by staining with
mAb 34-2-12S. At least two different transfectants expressing
each H2-D
 
d
 
 mutant were functionally tested, although results
from one of each are presented. YB2/0 targets expressing H2-D
 
d
 
,
H2-D
 
b
 
, or chimeric H2-D
 
d/b
 
 MHC I have been described previ-
ously (9).
 
Results and Discussion
 
Functional Recognition by Ly-49D Requires Both the 
 
a
 
1 
 
and
 
a
 
2
 
 Domains of H2-D
 
d
 
.
 
In previous studies, we examined
Ly-49A/H2-D
 
d
 
 interactions with chimeric MHC I that
combined exons for H2-D
 
d
 
 (a ligand for Ly-49A) and
H2-D
 
b
 
 (not a ligand for Ly-49A) using untransfected RNK-
16 and RNK.Ly-49A transfectants (9). In this study, we
tested the functional capacity of Ly-49D to recognize tar-
gets expressing these chimeric H2-D
 
b
 
/D
 
d
 
 MHC. As shown
in Fig. 1, RNK.Ly-49D transfectants specifically mediated
lysis of YB2/0 cells expressing intact H2-D
 
d
 
 or the chi-
meric MHC, 
 
a
 
1
 
D
 
d
 
a
 
2
 
D
 
d
 
a
 
3
 
D
 
b
 
 (Fig. 1, A and B), and lysis
was blocked by 12A8 F(ab
 
9
 
)
 
2
 
 (anti–Ly-49D). There was no
lysis of targets expressing 
 
a
 
1
 
D
 
b
 
a
 
2
 
D
 
b
 
a
 
3
 
D
 
d
 
 (data not shown).
Furthermore, RNK.Ly-49D cells failed to lyse targets ex-
pressing 
 
a
 
1
 
D
 
d
 
a
 
2
 
D
 
b
 
a
 
3
 
D
 
d
 
 (Fig. 1 C), indicating that Ly-49D,
like Ly-49A (Fig. 1 G), fails to recognize 
 
a
 
1
 
Dd paired with
a2Db. RNK.Ly-49D cells also failed to lyse targets express-
ing a1Dba2Dda3Dd (Fig. 1 D), indicating that Ly-49D, un-
like Ly-49A (Fig. 1 H), could not recognize a2Dd in the
context of a1Db. Thus, Ly-49D–mediated activation re-
quires the combined a1 and a2 domains of H2-Dd, whereas
Ly-49A can recognize a2 from Dd paired with a1 from Db.
Recognition of H2-Dd by Ly-49D but Not by Ly-49A Is
Highly Sensitive to Specific Single Amino Acid Changes in Either
the a1 or a2 Helices of H2-Dd. We next substituted indi-
vidual residues in the a1 or a2 helices of H2-Dd with the
corresponding H2-Db residues. We targeted three sites: (i)
the COOH-terminal a1 helix, corresponding to the human
MHC I region critical for recognition by killer inhibitory
receptors (KIRs; reference 10); (ii) single and paired muta-
tions at positions 73 (a1) and 156 (a2), which create a salt
bridge in H2-Db but not in H2-Dd (11, 12); and (iii) resi-
dues in the exposed a2 helix that differ between H2-Dd and
H2-Db. Sites targeted for mutation are shown in Fig. 2.
YB2/0 targets transfected with mutated H2-Dd were
selected for equivalent expression by binding to 34-2-
12S mAb (anti-Dd,  a3-specific; data not shown). Using
RNK.Ly-49D or RNK.Ly-49A transfectants as effectors,
we assessed the ability of mutant H2-Dd molecules to acti-
vate cytotoxicity through Ly-49D or to inhibit cytotoxicity
through Ly-49A.
As noted in our previous study, baseline lysis of untrans-
fected YB2/0 target cells by RNK.Ly49D transfectants is
much lower than lysis by RNK.Ly-49A transfectants (6).
Therefore, we do not base conclusions on differences in ly-
Figure 1. Functional recognition by Ly-49D requires both the a1 and
a2 domains of H2-Dd. Cytotoxicity by RNK.Ly-49D (left) and
RNK.Ly-49A (right) effectors was tested in the presence of blocking
12A8 F(ab9)2 fragments (r, anti-Ly-49A/Ly-49D), isotype-matched con-
trol F(ab9)2 fragments (d, 2C7), or media (h). Targets were YB2/0 cells
transfected with H2-Dd or H2-Dd/b chimeric molecules as indicated.449 Nakamura et al. Brief Definitive Report
sis observed between different transfected cell lines. Instead,
our conclusions are based on comparisons between lysis by
RNK transfectants with and without receptor-specific
blocking antibody. The specificity of the effect due to the
Ly-49 receptor was demonstrated by reversal of the effect
after blockade with receptor-specific mAb (intact or F(ab9)2
fragments). Blocking mAbs (A1, 12A8) did not stain un-
transfected RNK-16 or IL-2–activated NK cells from F344
rats (the strain from which RNK-16 is derived), indicating
that these antibodies do not recognize rat Ly-49 receptors
(data not shown). Moreover, receptor-specific mAb had no
effect on lysis of YB2/0.H2-Dd transfectants by wild-type
RNK-16 cells (9, 13). Finally, blocking mAbs had no effect
on lysis of YB2/0 or of YB2/0 transfected with Db, Kb, or
Kk by RNK-16, RNK.Ly-49A, or RNK.Ly-49D (6, 9,
and data not shown).
As shown in Fig. 3, single amino acid substitutions in the
a1 helix at positions 73, 80, or 83 all abrogated activation
of cytolysis through Ly-49D. Mutation at position 81 or
removal of the conserved N-linked glycosylation site at po-
sition 86 did not abrogate lysis through Ly-49D. In the a2
helix, mutations at positions 155, 156, or 169 also inter-
rupted recognition by Ly-49D. These results demonstrate
that Ly-49D–mediated activation is highly sensitive to sin-
gle amino acid changes in either of the a helices of H2-Dd.
In contrast, inhibitory recognition by Ly-49A was unim-
paired by the same single amino acid mutations (Fig. 3). In
addition, we found that mutagenesis of residues 73 and 156
had no effect on Ly-49A–mediated inhibition. This con-
flicts with results of Waldenstrom et al., who found im-
paired functional recognition by Ly-49A after substitution
at these sites with H2-Db residues, predicted to form a salt
bridge across the peptide binding groove (11, 12). This
contradiction is unexplained, although their studies used a
different target cell and nonclonal effector cells, perhaps de-
tecting an effect not specific to the Ly-49A receptor.
Mutations in the Floor of the Peptide Binding Groove of
H2-Dd Abrogate Functional Recognition of H2-Dd by both Ly-49D
and Ly-49A. Previous studies have demonstrated that
mAb 34-5-8S (H2-Dd  a1/a2-domain specific; reference
14), blocks recognition of H2-Dd by both Ly-49A (4, 7)
and Ly-49D (5, 6) and recognizes an epitope including res-
idues 92–116 in the a2 domain (9, 15). Therefore, we mu-
tated H2-Dd at sites within this region that differed be-
tween H2-Dd and H2-Db.
Residues in this region proved critical for recognition of
H2-Dd by both Ly-49D and Ly-49A. Each of three muta-
tions, W97Q, A99S, and W114L, abrogated activation by
Ly-49D (Fig. 4, G–I) and had a partial effect on functional
inhibitory recognition by Ly-49A (B–D). However, the
combination of all three mutations (97, 99, and 114) was
required to completely abrogate inhibitory recognition by
Ly-49A (Fig. 4 E). The triple A97Q/A99S/W114L muta-
tion and the single W97Q mutation were expressed at a
slightly lower level than the wild-type H2-Dd (Fig. 5, A
and C), because higher expressing transfectants could not
Figure 2. Location of mutated
amino acid residues in H2-Dd.
The molecular graphics image
was created by H. Houtkooper,
University of California, San
Francisco, Computer Graphics
Laboratory, with the MidasPlus
modeling system. The image is
based on Protein Data Bank co-
ordinates 1bii (26).450 Differences between Ly-49D and Ly-49A Interactions with H2-Dd
be obtained. Thus, it remains possible that a triple mutant
expressed at higher levels might retain some Ly-49A inhi-
bition.
Interestingly these critical a2 domain residues lie in the
b-pleats forming the floor of the peptide binding groove
(16, 17), demonstrating that residues in the H2-Dd peptide
binding platform are important in recognition by both Ly-
49D and Ly-49A. This was unexpected, as none of these
residues is directly solvent accessible (16, 17). The tryp-
tophan residues at positions 97 and 114 form a unique hy-
drophobic ridge in the floor of the antigen binding groove
that severely constrains the bound antigenic peptide at resi-
due P3 (16, 17). Only proline at anchor position 3 fits the
steric and hydrophobic constraints of the cleft (16–18).
Thus, the mutation of the tryptophans might permit other
peptide residues at this anchor site.
The two b-pleats containing these critical sites are con-
nected by a loop that protrudes from beneath the a2 helix.
This loop contains polymorphic residues at positions 103,
104, and 107. Mutation at position 104 abrogated recogni-
tion by Ly-49D, but it did not alter recognition by Ly-49A
(Fig. 3). This result again demonstrates the sensitivity of
Ly-49D to mutations throughout H2-Dd, and the contrast-
ing insensitivity of Ly-49A.
Mutations in H2-Dd Demonstrate that Functional Recognition
by Ly-49A or Ly-49D Does Not Strictly Correlate with Binding
by the mAb 34-5-8S. Like Ly-49A, binding by mAb 34-
5-8S to H2-Dd requires a conformational epitope depen-
dent on occupancy of the peptide binding groove but not
on peptide sequence, and 34-5-8S is the only known anti–
H2-Dd mAb that blocks Ly-49A/H2-Dd interactions (7).
We examined 34-5-8S binding to the H2-Dd mutants that
differed in their functional recognition by Ly-49A and Ly-
49D. The triple mutation W97Q/A99S/W114L in H2-
Dd, which abrogated functional recognition by Ly-49A and
Ly-49D, also eliminated binding by 34-5-8S (Fig. 5 D).
However, we did not observe an exact correlation between
binding to 34-5-8S and functional inhibition through Ly-
Figure 3. Recognition of H2-Dd by Ly-49D but not by Ly-49A is
highly sensitive to specific single amino acid changes in either the a1 do-
main or the a2 domain of H2-Dd. RNK.Ly-49D (right) and RNK.Ly-
49A (left) effectors were tested for lysis of YB2/0 targets transfected with
intact H2-Dd, H2-Db, or H2-Dd mutated to the corresponding residue of
H2-Db as indicated in the left-hand column. Lysis of target cells is shown
at an E/T ratio of 50:1. Lysis by RNK.Ly-49A effectors was assessed in
the presence of anti–Ly-49A (A1, black bars) or no blocking mAb (spot-
ted bars). Lysis by RNK.Ly-49D effectors was assessed in the presence of
anti–Ly-49D F(ab9)2 fragments (12A8, hatched bars) or no antibody
(white bars).
Figure 4. Mutations in the floor of the peptide binding groove of
H2-Dd abrogate functional recognition of H2-Dd by both Ly-49D and
Ly-49A. Lysis by RNK.Ly-49D (right) and RNK.Ly-49A (left) effectors
were tested in the presence of blocking 12A8 F(ab9)2 fragments (r, anti-
Ly-49A/Ly-49D) or no antibody (h) against YB2/0 targets expressing
H2-Dd or mutated H2-Dd as indicated in the left-hand column. In panels
E and J, H2-Dd is mutated at all three sites (97, 99, and 114).451 Nakamura et al. Brief Definitive Report
49A. Mutant E104G mediated Ly-49A–dependent inhibi-
tion but demonstrated less binding to 34-5-8S (Fig. 5 F),
whereas W114L retained 34-5-8S binding but mediated
decreased inhibition through Ly-49A (Fig. 5 L). Notably,
single residue mutations in the a helices of H2-Dd pre-
served 34-5-8S binding, but failed to activate Ly-49D.
Thus, the requirements for binding by 34-5-8S closely
overlap with, but are not identical to, the requirements for
recognition by Ly-49A. In contrast, the 34-5-8S epitope
was not sufficient for recognition by Ly-49D.
Our studies can now be interpreted in light of the recent
publication of the crystal structure of the Ly49A receptor
bound to H2-Dd (19). In these studies, Ly-49A was ob-
served to contact H2-Dd through two distinct interfaces. At
the first site, predicted to be important in NK/target cell
interactions, Ly-49A binds to one side of the exposed
MHC I a-helices that form the peptide binding platform,
but does not contact the peptide itself. Regions of Ly-49A
involved in this site of H2-Dd interaction include the loop
preceding the b3 strand, strand b4, and the connecting
loop to b5. Interestingly, this is a region where the se-
quences of Ly49A and Ly49D diverge, with differences at
residues 234, 243, 244, and 248 (19). Notably, Ly-49D
contains two large aromatic residues that are not found in
Ly-49A: phenylalanine at 234 and tyrosine at 244. If Ly-
49D interacts with H2-Dd at the same interface, the pres-
ence of these residues might destabilize binding by Ly-49D,
rendering it more sensitive to slight alterations in H2-Dd.
The Ly-49A–binding site on H2-Dd includes regions in
both the a1 helix and a2 helix adjacent to the N-linked
glycosylation site at position 176. Within this site, allelic
differences between H2-Dd and H2-Db are found only at
positions 50 and 169 (20). Notably these are both charged
arginine residues in H2-Dd. We found that mutation
R169H did not abrogate Ly-49A–mediated interactions
(Fig. 2). The residue at position 50 also may not be critical
individually, since a chimeric MHC with the entire a1 re-
gion of H2-Db in place of H2-Dd-a1 still mediates inhibi-
tion through Ly-49A (9). Thus, although both residues
may be important in recognition of H2-Dd by Ly-49A, the
Figure 5. Mutations in H2-Dd demonstrate that
functional recognition by Ly-49A and Ly-49D
does not strictly correlate with binding by the mAb
34-5-8S. YB2/0 tumor target cells expressing
H2-Dd or H2-Dd mutated at the indicated residues
were stained with an anti–H2-Dd mAb (34-2-12S
[a3] or 34-5-8S [a1,2]). Overlay (black line) shows
staining of YB2/0 cells transfected with H2-Db as
background which was similar to staining of un-
transfected YB2/0 cells (not shown). Transfectants
were initially selected for equivalent expression as
assessed by 34-2-12S binding (A, C, E, G, I, K, M,
and O, gray histogram) then assessed for 34-5-8S
binding (B, D, F, H, J, L, N, P, gray histogram).
For comparison, relative inhibition by Ly-49A and
activation by Ly-49D are shown at the right.452 Differences between Ly-49D and Ly-49A Interactions with H2-Dd
allelic specificity may indeed depend on conformational in-
teractions independent of the contact residues. In support
of the latter, we found critical residues in H2-Dd that were
located in the floor of the peptide binding groove.
Ly-49A recognition of H2-Dd depends on occupancy of
the peptide binding groove, yet Ly-49A/H2-Dd interac-
tions are sustained by divergent peptides bound to H2-Dd
(7, 21). The functionally significant mutations we have
identified in the floor of the peptide binding platform may
alter the conformation of the platform itself either directly
or through changes in bound peptide, possibly through al-
teration of the P3 binding pocket.
Interestingly, recent studies using soluble H2 tetramers
have found that MHC I recognition by other inhibitory
Ly-49 receptors is influenced by certain peptides (22), sim-
ilar to findings regarding MHC I recognition by human
KIR (23). Involvement of peptide in MHC I recognition
by Ly-49D and other activating receptors has yet to be de-
fined.
The crystal structure of Ly-49A and H2-Dd revealed a
second site of interaction involving a cavity beneath the
H2-Dd peptide binding platform that partially includes the
CD8 binding site (19). There are no polymorphic H2-Dd
residues in this contact region to account for the allelic
specificity observed in Ly-49A interactions, but it remains
possible that conformation of this region is affected signifi-
cantly by distant polymorphisms. It was proposed that the
second site of Ly-49A and MHC I interaction might be
important in interactions on the NK cell itself (19). We did
not address this hypothesis because our studies tested only
interactions between Ly-49A and H2-Dd on different cells.
Our demonstration that Ly-49A and Ly-49D differ
markedly in their requirements for binding to H2-Dd is
consistent with evidence that activating and inhibitory re-
ceptors differ in their binding kinetics and affinities. Studies
with soluble human KIR receptors revealed differences in
the kinetics of MHC I binding, with activating receptors
binding so weakly that rates were difficult to quantify (24–
26). Recent studies were also unable to detect binding of
activating Ly-49D to soluble tetrameric H2-Dd (22). Our
finding that functional recognition of H2-Dd by Ly-49D is
extremely sensitive to single amino acid changes in H2-Dd
may reflect a relatively low-avidity receptor/ligand inter-
action that can be easily disrupted by subtle changes in
H2-Dd. Alternatively, binding by activating receptors may
require involvement of specific peptides or coreceptors.
Both activating and inhibitory receptors have been iden-
tified within each of the major MHC I binding NK recep-
tor families (KIR, Ly-49, CD94/NKG2) in humans and
rodents, suggesting an important role for these opposing
molecules in balancing receptor function. Aside from
H2-Dd, Ly-49D responds to other mouse MHC I as well as
certain xenogeneic ligands (5, 13, 27). Thus, Ly-49D may
recognize a diverse repertoire that only partially overlaps
with inhibitory Ly-49 receptor ligands. Our demonstration
that Ly-49D and Ly-49A differ in ligand recognition has
implications regarding the integration of NK responses, be-
cause Ly-49A and Ly-49D receptors may be affected differ-
entially by changes in MHC I antigens or, possibly, by pep-
tides bound to MHC I during immune surveillance.
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